The Future of CDK4/6 Inhibitors

Discussion in this segment centers on the evolving trajectory of CDK4/6 inhibitors, from metastatic disease into earlier treatment lines. Panelists anticipate continued exploration of these agents in adjuvant and neoadjuvant contexts, potentially redefining long-term management strategies. Clinical trials are already assessing whether early intervention can prevent metastatic relapse in high-risk patients.

The conversation also addresses research priorities, including biomarkers predictive of response, resistance mechanisms, and optimal sequencing with other targeted therapies. Participants stress the need for robust real-world datasets to confirm efficacy in underrepresented groups. Moreover, they emphasize ongoing efforts to minimize toxicity and cost burden while maintaining access.

Looking ahead, panelists envision CDK4/6 inhibition remaining central to hormone receptor–positive breast cancer therapy, complemented by a growing ecosystem of precision-based combinations and adaptive treatment strategies.